Traders purchased shares of Amgen, Inc. (NASDAQ:AMGN) on weakness during trading hours on Friday. $449.23 million flowed into the stock on the tick-up and $269.71 million flowed out of the stock on the tick-down, for a money net flow of $179.52 million into the stock. Of all companies tracked, Amgen had the 6th highest net in-flow for the day. Amgen traded down ($5.00) for the day and closed at $177.47
A number of equities research analysts have recently weighed in on AMGN shares. Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a research note on Monday. Citigroup boosted their target price on Amgen from $204.00 to $210.00 and gave the company a “neutral” rating in a research note on Friday, January 4th. Goldman Sachs Group reissued a “buy” rating and issued a $232.00 target price on shares of Amgen in a research note on Thursday, January 17th. Oppenheimer set a $224.00 target price on Amgen and gave the company a “buy” rating in a research note on Sunday, January 27th. Finally, Royal Bank of Canada reissued a “neutral” rating on shares of Amgen in a research note on Friday, February 1st. Eleven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $209.11.
The firm has a market cap of $109.31 billion, a PE ratio of 12.32, a PEG ratio of 2.34 and a beta of 1.21. The company has a quick ratio of 2.57, a current ratio of 2.79 and a debt-to-equity ratio of 2.36.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, January 29th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.26 by $0.16. Amgen had a return on equity of 66.74% and a net margin of 35.35%. The company had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $5.88 billion. During the same quarter in the previous year, the business earned $2.89 EPS. On average, analysts forecast that Amgen, Inc. will post 13.96 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a dividend of $1.45 per share. The ex-dividend date is Thursday, May 16th. This represents a $5.80 dividend on an annualized basis and a yield of 3.27%. Amgen’s dividend payout ratio is presently 40.28%.
In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, February 7th. The stock was sold at an average price of $190.00, for a total transaction of $380,000.00. Following the transaction, the director now owns 14,988 shares in the company, valued at approximately $2,847,720. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders have sold 6,000 shares of company stock worth $1,144,120. 0.27% of the stock is owned by company insiders.
Several hedge funds have recently bought and sold shares of AMGN. Blue Fin Capital Inc. lifted its position in Amgen by 10.0% in the third quarter. Blue Fin Capital Inc. now owns 7,449 shares of the medical research company’s stock worth $1,544,000 after purchasing an additional 677 shares during the period. Vident Investment Advisory LLC raised its stake in Amgen by 135.5% during the third quarter. Vident Investment Advisory LLC now owns 5,238 shares of the medical research company’s stock worth $1,086,000 after acquiring an additional 3,014 shares in the last quarter. Macquarie Group Ltd. raised its stake in Amgen by 6.5% during the third quarter. Macquarie Group Ltd. now owns 168,607 shares of the medical research company’s stock worth $34,952,000 after acquiring an additional 10,237 shares in the last quarter. Kentucky Retirement Systems acquired a new position in Amgen during the third quarter worth $7,108,000. Finally, Neuberger Berman Group LLC raised its stake in Amgen by 3.9% during the third quarter. Neuberger Berman Group LLC now owns 154,783 shares of the medical research company’s stock worth $32,085,000 after acquiring an additional 5,836 shares in the last quarter. Hedge funds and other institutional investors own 79.18% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Traders Buy Shares of Amgen (AMGN) on Weakness” was published by Zolmax and is the property of of Zolmax. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://zolmax.com/investing/traders-buy-shares-of-amgen-amgn-on-weakness/3048147.html.
About Amgen (NASDAQ:AMGN)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Read More: When is a capital gain realized?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.